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Growth differentiation factor 15 (GDF15) is a stress molecule produced in response to
mitochondrial, metabolic and inflammatory stress with a number of beneficial effects on
metabolism. However, at the level of skeletal muscle it is still unclear whether GDF15 is
beneficial or detrimental. The aim of the study was to analyse the levels of circulating
GDF15 in people of different age, characterized by different level of physical activity
and to seek for correlation with hematological parameters related to inflammation. The
plasma concentration of GDF15 was determined in a total of 228 subjects in the age
range from 18 to 83 years. These subjects were recruited and divided into three different
groups based on the level of physical activity: inactive patients with lower limb mobility
impairment, active subjects represented by amateur endurance cyclists, and healthy
controls taken from the general population. Cyclists were sampled before and after
a strenuous physical bout (long distance cycling race). The plasma levels of GDF15
increase with age and are inversely associated with active lifestyle. In particular, at any
age, circulating GDF15 is significantly higher in inactive patients and significantly lower in
active people, such as cyclists before the race, with respect to control subjects. However,
the strenuous physical exercise causes in cyclists a dramatic increase of GDF15 plasma
levels, that after the race are similar to that of patients. Moreover, GDF15 plasma levels
significantly correlate with quadriceps torque in patients and with the number of total
leukocytes, neutrophils and lymphocytes in both cyclists (before and after race) and
patients. Taken together, our data indicate that GDF15 is associated with decreased
muscle performance and increased inflammation.
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INTRODUCTION
Growth differentiation factor 15 (GDF15), also known as macrophage inhibitory cytokine 1
(MIC-1), is a stress responsive member of the transforming growth factor-β (TGF-β) cytokine
superfamily, discovered in 1997 (1). GDF15 modulates appetite and energy metabolism possibly
by regulating mitochondrial functions, such as mitochondrial biogenesis, thermogenesis, and fatty
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acid metabolism (2). Interestingly, mice overexpressing human
GDF15 display increased life span (3). However, the role
of GDF15 in promoting health or disease is still debated.
There are in fact several evidences indicating that GDF15
levels are associated to progression of many diseases, such as
cardiovascular diseases, insulin resistance and type 2 diabetes,
neurodegeneration, renal chronic disease and cancer, but also
to the limitation of the damage caused by stress and injuries
(4–8). Accordingly, GDF15 has recently emerged as a potential
biomarker for the aging process and many age-related diseases
(2, 9–11). As far as muscle atrophy and sarcopenia, there is debate
on whether GDF15 is to be considered protective or detrimental.
Recent data from animal models showed that GDF15 is able to
induce muscle fiber apoptosis (12, 13), but also the ablation of
GDF15 resulted in an amplified skeletal muscle post exercise
stress response, with a bigger increase of markers of muscle
stress (Atf3, Atf6, and Xbp1s) (14). In humans, circulating
GDF15 levels are significantly higher in subjects with sarcopenia
or muscle atrophy (15–17) with respect to healthy subjects of
comparable age. Recent studies demonstrate that GDF15 levels
are negatively correlated with skeletal muscle mass index, hand-
grip strength, muscle cross-sectional area and thickness (15, 18).
Moreover, the loss of muscle mass observed in cachectic patients
is mediated at least in part by the activity of GDF15 (19). On
the other hand, it is known that physical exercise can effectively
combat muscle atrophy, but is characterized by an increase in
the level of circulating GDF15 (20–22). This could be explained
by the fact that, as recently proposed, skeletal muscle is not the
primary source of GDF15 (22). Finally, it is known that GDF15 is
a stress molecule that is produced in response to mitochondrial,
metabolic and inflammatory stresses (2, 23). To this regard, it
is worth noting that a chronic state of low-grade inflammation,
termed inflammaging, characterizes old people and is at the basis
of many age-related diseases (24–26).
The aim of this study is to analyse the levels of circulating
GDF15 in people of different age characterized by different levels
of physical activity and to seek for correlation with hematological
parameters related to inflammation. To this purpose, we studied
three groups of subjects: 1. patients with chronic lower limb
mobility impairment as a model of physical inactivity; 2. a group
of amateur endurance cyclists as a model of physical activity; 3.
and, age-matched subjects recruited from the general population,
not actively exercising. Cyclists were sampled before and after
a strenuous physical bout (a 130-km long distance road cycling
race with a total uphill gradient of 1,871 m).
METHODS
Subjects
In the present study, a total of 228 subjects in the age range
from 18 to 83 years were recruited and divided into three
different groups based on the level of physical activity: patients
with lower limb mobility impairment (hereinafter patients),
cyclists and controls. Patients suffered of coxarthrosis or hip
dysplasia, causing them to be chronically unable to walk or
exercising, and were therefore considered a model for prolonged
physical inactivity. All subjects were further divided according
to their age into the following groups: young, adult, late
TABLE 1 | Experimental sample description.
Cyclists Controls Patients
n◦ Young
Age range
(average, ±SD)
10 (2F, 8M)
18–39 yrs
(30.3, ± 6.0)
15 (9F, 6M)
18–39 yrs
(29.1, ± 7.6)
15 (5F, 10M)
24–39 yrs
(33.0, ± 4.8)
n◦ Adult
Age range
(average, ±SD)
32 (4F, 28M)
40–60 yrs
(49.8, ± 5.8)
21 (5F, 16M)
41–60 yrs
(51.7, ± 6.5)
20 (8F, 12M)
43–60 yrs
(51.4, ± 5.6)
n◦ Late adult
Age range
(average, ±SD)
5 (0F, 5M)
61–71 yrs
(64.6, ± 6.0)
32 (14F, 18M)
63–71 yrs
(67.7, ± 2.8)
17 (12F, 5M)
61–70 yrs
(65.3, ± 2.5)
n◦ Old
Age range
(average, ±SD)
____ 43 (13F, 30M)
72–82 yrs
(75.6, ± 3.1)
12 (7F, 5M)
73–83 yrs
(79.6, ± 3.5)
Subjects are divided in four groups (in bold) according their age: Young, Adult, Late adult,
Old. Each age group includes subjects with different levels of physical activity: Cyclists,
Controls, Patients. The number (n◦) of the subjects for each groups are reported in bold.
adult, old (Table 1). All subjects were enrolled in Italy in the
framework of the following projects: the EU project MYOAGE
for patients and controls, the “Novecolli Life” project promoted
by Italian National Transplant Center for cyclists. The study
protocols were approved by the Ethical Committee of Istituto
Ortopedico Rizzoli, Bologna, Italy (ethical clearance no. 10823
issued on April 26, 2010) and by the Ethical Committees of
the Italian Institute of Health (ethical clearance prot.no. 14/420
issued on March 7, 2014), respectively. All subjects signed an
informed consent before entering the study. Age (>18 years)
and ability to provide informed consent were inclusion criteria.
Exclusion criteria were the presence of chronic kidney or liver
diseases, unstable cardiovascular pathology, bleeding disorders,
diabetes, neuromuscular disorders, systemic infections, major
psychological problems, malignant neoplasia and/or a current
therapy with immune suppressor drugs (like cyclosporine,
methotrexate, glucocorticoids, etc.) or anticoagulant drugs,
history of alcohol or drug abuse.
The Race
Briefly, the race, known as “Nove Colli,” is a long-distance cycling
road race that takes place in Romagna (Forlì-Cesena and Rimini,
Italy). The characteristics of the route were: length, 130 km;
total uphill gradient, 1,871m; uphill riding, 50 km over 4 hills;
downhill riding, 46 km; flat terrain, 34 km; maximum riding time
allowed, 7.5 h. For further details see Mosconi et al. (27, 28).
Sampling and Data Collection
For patients and controls, blood was drawn in the morning
after overnight fasting. All samples were processed immediately
to collect plasma. For cyclists, the collection of venous blood
(30mL) samples was done at three different times: time 1 (T1),
the day before the race, time 2 (T2), immediately after crossing
the finish line, and time 3 (T3), 18–24 h after competing.
Plasma was obtained within 4 h from venipuncture by
centrifugation at 2,000 g for 20min at 4◦C, rapidly frozen and
stored at−80◦C.
Blood cells and creatinine were measured by standard
biochemical assays. White blood cell counts for cyclists
(both T1 and T2) and patients divided for age group are
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presented in Supplementary Table 1. For cyclists, both at T1
and T2, three markers of cellular inflammation were calculated
(Supplementary Table 2) as described below. The neutrophil-
lymphocyte ratio (NLR) was calculated on the basis of absolute
neutrophil (N; ×103/microL) and lymphocyte (L; ×103/microL)
blood counts, using the formula: NLR = N/L. The platelet-
lymphocyte ratio (PLR) was calculated on the basis of peripheral
platelet (P; ×103/microLiter) and lymphocyte (L; ×103/microL)
blood counts, using the formula: PLR = P/L. The systemic
immune-inflammation index (SII) was calculated on the basis
of peripheral platelet (P), neutrophil (N), and lymphocyte (L)
blood counts, using the following formula: SII= P ∗ N/L. All the
inflammatory markers are ratios thus do not have a unit (29, 30).
Estimated glomerular filtration rate (eGFR) was calculated
according to CKD-EPI (Chronic Kidney Disease Epidemiology
Collaboration) equation based on serum creatinine, age, sex
and ethnicity. (31). Body mass index (BMI) was calculated
as weight in kilograms divided by the square of the height
in meters (kg/m2). For patients, maximal quadriceps torque
and vastus lateralis thickness were measured by using a
Handifor R© dynamometer and portable ultrasound (Mylab25,
Esaote), respectively, as reported in (32).
GDF15 concentration was determined in plasma samples
by ELISA assay using commercial kits, R&D (DGD150),
according to the manufacturer’s instructions. All the samples
were measured in duplicate and the analyses were performed in a
blind setup.
Statistical Analysis
The data were analyzed with non-parametric tests since they did
not follow a normal distribution. In particular, the comparisons
among cyclists, controls and patients in the different age groups
FIGURE 1 | Plasma levels of GDF15 increase with age and are negatively associated with active lifestyle. (A) Regression analysis of circulating GDF15 and age in
cyclists, controls and patients. (B–D) Circulating plasma levels of GDF15 in young cyclists (T1), controls and patients (B); in adult cyclists (T1), controls and patients
(C); in late adult cyclists (T1), controls and patients (D). Data are expressed as mean ± SE and p-values refer to Kruskal-Wallis test. (E) Circulating plasma levels of
GDF15 in old controls and patients, data are expressed as mean ± SE and p-values refer to Mann-Whitney test. (F) Regression analysis of circulating GDF15 vs.
quadriceps maximal torque normalized for age and vastus lateralis muscle thickness in patients.
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FIGURE 2 | GDF15 plasma levels in cyclists before and after the race. (A) The differences among plasma GDF15 levels before the race (T1), immediately after the
race (T2), and after 18–24 h from the race (T3) were analyzed. Data are expressed as mean ± SE p-values refer to Friedman test. (B–D) Circulating plasma levels of
GDF15 in young cyclists (T2), controls and patients (B); in adult cyclists (T2), controls and patients (C); in late adult cyclists (T2), controls and patients (D). Data are
expressed as mean ± SE and p-values refer to Kruskal-Wallis test.
(young, adult, late adult) were performed by using Kruskal-
Wallis test with a Steel post-hoc test, while the comparison
between patients and controls in old group was performed by
Mann-Withney test. To compare the GDF15 levels in cyclists at
different times of the race (T1, T2, T3) we performed a Friedman
test. The relationship among GDF15 levels and age, white blood
cells, hematological markers of cellular inflammation (NLR, PLR,
SII), creatinine, eGFR, and quadriceps torque were calculated
by Spearman rank correlation test and regression analysis.
Significance was accepted as p< 0.05. Data are expressed asmean
± SE. All data were analyzed using the SPSS 25.0 for Windows
software (SPSS Inc.; Chicago, IL, USA).
RESULTS
Plasma Levels of GDF15 Increase With Age
and Are Negatively Associated With Active
Lifestyle
Linear regression analysis showed that GDF15 plasma levels
were significantly associated with age for all the 228 subjects
(Figure 1A). Spearman rank correlation coefficient and p-value
are: ρ = 0.741, p < 0.0001. This age-related increase of plasma
GDF15 was evident irrespective to the level of physical activity of
the subjects, confirming previous data on GDF15 and age (10).
However, when the subjects were subdivided on the basis of their
age and level of physical activity (as described in Materials and
Methods Section), the plasma levels of GDF15 were significantly
higher in inactive patients and significantly lower in active people
such as cyclists with respect to control subjects, in young, adult
and late adult people (Figures 1B–D). For ages over 72 years,
only patients and controls were available but also in this case the
same trend was observed (Figure 1E). The relationship between
physical activity and GDF15 was also analyzed considering BMI
as a covariate, and the results remained the same (data not
shown). Therefore, it seems that the level of physical activity
determines the plasma levels of GDF15 at any age. For patients,
the values of maximal quadriceps torque normalized on vastus
lateralis muscle thickness were available, and these values,
considering age as a covariate, resulted inversely correlated to
GDF15 plasma levels; Spearman rank correlation coefficient and
p-value are: ρ = −0.449 and p < 0.0001 (Figure 1F). Similar
results were obtained when quadriceps torque was normalized
on total BMI (data not shown). However, as already reported,
a strenuous physical exercise (in our case, the long-distance
cycling race) is able to cause a dramatic increase of plasma
GDF15, as evidenced by the difference between T2 (immediately
after the race) and T1 (before the race) (Figure 2A). After 18–
24 h from the race (T3), the levels of GDF15 tend to return
at baseline level, even if these levels remain significantly higher
than T1 (Figure 2A). We also compared the levels of GDF15
at T2 with those observed in controls and patients of similar
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FIGURE 3 | Regression analysis of GDF15 plasma levels with hematological parameters. (A–C) Regression analysis of circulating GDF15 levels and leukocytes (A),
neutrophils (B), lymphocytes (C), in cyclists before the race (T1), immediately after the race (T2), and in patients.
age. In the group of young subjects GDF15 levels resulted
significantly higher with respect to controls and similar to
patients (Figure 2B), while in the adult group the GDF15 levels
resulted significantly higher with respect to controls and patients
(Figure 2C). In the group of late adults, no difference was present
(Figure 2D).
Relationship Among Plasma Levels of
GDF15 With Hematological Parameters
Related to the Inflammatory Response and
Renal Function
It is known that GDF15 is responsive to mitochondrial
stress and inflammation, two conditions that apply under
strenuous physical exercise (33). We then sought for associations
with hematological parameters associated to an inflammatory
response. In cyclists, before (T1) and immediately after (T2) the
race, regression analysis has shown an association between white
blood cells and GDF15 plasma levels (Figures 3A–C). Moreover,
GDF15 plasma levels significantly and positively correlated with
the number of total leukocytes (T1: ρ = 0.311 and p = 0.036,
T2: ρ = 0.343 and p = 0.019) (Figure 3A) and neutrophils (T1:
ρ = 0.346 and p = 0.018, T2: ρ = 0.621 and p < 0.0001)
(Figure 3B), and negatively with lymphocytes (T1: ρ = −0.332
and p = 0.024, T2: ρ = −0.613) (Figure 3C). Interestingly, the
same associations were found for patients (Figures 3A–C) and in
this case the Spearman rank correlation coefficients were similar
to those observed for cyclists’ T2 (leukocytes: ρ = 0.388 and
p = 0.001; neutrophils: ρ = 0.519 and p < 0.0001; lymphocytes:
ρ =−0.536 and p< 0.0001). Therefore, it seems that a strenuous
physical exercise produces a transient state of stress that, as far as
GDF15 and inflammatory parameters, is similar to that present
in patients.
Recently, several studies have proposed NLR, PLR and SII
as white blood-cell-based inflammatory markers. The levels of
these inflammatory indices are in fact elevated in individuals
with chronic inflammation and several age-related pathologies
(29, 30). To evaluate whether strenuous exercise influences
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FIGURE 4 | Regression analysis of GDF15 plasma levels with hematological markers of cellular inflammation in cyclists before (T1) and immediately after (T2) the race.
(A) Regression analysis of circulating GDF15 levels and neutrophil/lymphocyte ratio (NLR); (B) regression analysis of circulating GDF15 levels and platelet/lymphocyte
ratio (PLR); (C) regression analysis of circulating GDF15 levels and systemic immune-inflammation index (SII).
the relationship between GDF15 plasma levels and these
inflammatory markers, a regression analysis in cyclists at T1 and
T2 was performed. We observed significant association between
GDF15 and NLR, and GDF15 and SII, both at T1 and T2
(Figures 4A,C); while the association between GDF15 and PLR
is present only at T2 (Figure 4B). Interestingly, these associations
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FIGURE 5 | Regression analysis of GDF15 plasma levels with estimated glomerular filtration rate (eGFR) and creatinine. (A,B) Regression analysis of circulating
GDF15 and eGFR (A), creatinine (B) in cyclists before the race (T1), immediately after the race (T2).
are stronger at T2, as also confirmed by Spearman’s correlation
analysis. In this case in fact, only at T2 the levels of GDF15
significantly correlate with these markers (NLR: ρ = 0.616 and
p < 0.0001; PLR: ρ = 0.567 and p < 0.0001; SII: ρ = 0.580
and p< 0.0001).
It has been recently reported that upon metformin treatment,
GDF15 is increased in distal intestine and kidney (34), and an
intense sport exercise induces acute renal stress (35), with an
increase in creatinine levels and a decline of estimated glomerular
filtration rate (eGFR), as indices of renal function (36). We
then evaluated in cyclists at T1 and T2 the possible relationship
among GDF15 levels, creatinine, and eGFR. We observed that
GDF15 levels were associated with creatinine (Figure 5A) and
eGFR (Figure 5B). Furthermore, according to the Spearman’s
correlation analysis, GDF15 plasma levels, both at T1 and
T2, positively correlated with creatinine (T1: ρ = 0.316 and
p = 0.032, T2: ρ = 0.422 and p = 0.003), and negatively with
eGFR (T1: ρ = −0.506 and p < 0.0001, T2: ρ = −0.486 and
p = 0.001). These results suggest that the elevation of GDF15
observed during a strenuous physical exercise is associated with
renal stress.
DISCUSSION
GDF15 is a cytokine that was considered expressed only by a
limited number of tissues, such as liver, lung and kidney, as
well as by the placental trophoblast (37). More recently it has
been demonstrated that GDF15 is responsive to mitochondrial
stresses (38), and, according to the theory that aging is associated
with increased mitochondrial dysfunction, elevated circulating
levels of GDF15 are found in elderly people and centenarians
(9–11). As it is known that strenuous exercise induces GDF15
expression (20–22), it has been hypothesized that also skeletal
muscle can be a source of this cytokine. Accordingly, GDF15 is
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expressed in muscles from mouse models of aging and inactivity
(12, 14). However, this idea has been recently challenged, as
the concentrations of GDF15 during a physical exercise resulted
similar in arterial and venous blood across the exercised leg
(22). Our results are in favor of the idea that skeletal muscle
is not the primary source of GDF15, as its basal levels are
lower in actively exercising people like cyclists with respect to
age-matched controls. However, this does not exclude at all
that skeletal muscles can produce a little amount of GDF15.
Moreover, after a bout of strenuous physical activity, the levels of
GDF15 are correlated with markers of kidney injury, suggesting
that, according to literature data (34), the elevation of GDF15
may be a response to an injury to other organs, including
the kidney.
Whether GDF15 is beneficial or detrimental for skeletal
muscle is still debated. It has been previously reported that
GDF15 causes anorexia/cachexia via its impact on energy
metabolism (18) and, accordingly, it is found inversely associated
with muscle mass (39). Moreover, even though its receptor,
GDNF family receptor α-like (GFRAL), has not been found
expressed in muscle (40) GDF15 is able to induce muscle
fiber apoptosis via phosphorylation of STAT3 (13). On the
other side, as mentioned, the GDF15 knockout determines
the elevation of markers of muscle stress (Atf3, Atf6, and
Xbp1s) upon exercise (14). Our data suggest that GDF15 is
inversely associated with muscle health, as it is elevated in
patients with lower limb mobility impairment and inversely
associated with their quadriceps maximal torque. It is at present
unclear whether this association is causal or not. In order to
reconcile our data with those demonstrating a beneficial role for
GDF15, we can hypothesize that transient peaks of GDF15 are
stimulatory/homeostatic, whereas long-lasting elevated systemic
levels can turn detrimental. This could be the case of patients with
lower limb mobility impairment.
Another alternative possibility is that GDF15 acts in synergy
or in opposition with other factors. Interestingly, some samples
from cyclists used in this study were previously assayed for the
expression of inflammatory mediators such as IL-6, TNF-α, and
IFN-γ that resulted dramatically increased after the race (33). To
this regard, it is worth noting that GDF15 is also responsive to
inflammation, mostly via p53 (41). It has indeed been shown
that GDF15 is a direct target gene of p53. Recently, it has
been demonstrated that GDF15 is necessary for tolerance to
inflammation induced by viral or bacterial infections (23). It has
also a clear anti-inflammatory activity in experimental models
of liver injury and myocardial infarction (42, 43). In particular,
GDF15 attenuates the LPS-induced production of classical pro-
inflammatory cytokines such as TNF-a, IL-1β and IL-6 in Kupffer
cells (42), and is able to inhibit the chemokine-activated leukocyte
arrest on the myocardial endothelium of infarcted heart (43).
Here we show that GDF15 levels are clearly associated with
hematological parameters related to inflammation, i.e., increased
number of leukocytes (in particular neutrophils) and decreased
number of lymphocytes, in both cyclists and patients. Thus, it is
possible that the net effect of GDF15 on muscle health depends
on the fine interaction with inflammatory mediators.
Given its responsiveness to inflammation and reported anti-
inflammatory effects, the elevated levels of GDF15 can be
interpreted as an automatic mechanism to blunt the detrimental
effects of inflammation (acute like a strenuous bout of physical
activity, or chronic like that present in inactive patients). It has
been previously reported that a chronic, subclinical inflammation
(inflammaging) is a typical feature of old people. Therefore, it
is tempting to speculate that GDF15 is elevated in the elderly at
least in part as a consequence of inflammaging, and that GDF15
could be added to the list of anti-inflammagingmediators. Elderly
people are also characterized by a loss of muscle mass and power
(44), and we have reported that GDF15 levels are very high in
old people and centenarians (10). Therefore, due to its wasting
activity on muscle, it is thus conceivable that the elevated levels
of GDF15 in elderly people and particularly in the oldest old can
be a trait-d’union between inflammaging and the observed loss of
muscle mass and power.
Finally, it can be hypothesized that people with less
inflammaging have consequently a lower production of GDF15.
A corollary of this hypothesis is that the positive effects of
GDF15 are likely not enough to overcome the detrimental
ones brought by inflammaging. These considerations possibly
indicate GDF15 as a target for future pharmacological or life-
style interventions to implement healthy aging and longevity,
whose goal would be to obtain the beneficial effects of GDF15
avoiding the detrimental ones. Future studies are needed in
this perspective.
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